

Mariusz L Hartman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3463866/publications.pdf>

Version: 2024-02-01

23
papers

856
citations

516710

16
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

1482
citing authors

#	ARTICLE	IF	CITATIONS
1	BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells. <i>Cancer Letters</i> , 2021, 499, 122-136.	7.2	13
2	Inhibitors of HSP90 in melanoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 12-28.	4.9	35
3	TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAFV600E melanoma cells. <i>Archives of Dermatological Research</i> , 2020, 312, 385-392.	1.9	3
4	17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF- κ B) Activity in Patient-Derived Melanoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3749.	4.1	7
5	Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity. <i>Cells</i> , 2020, 9, 142.	4.1	41
6	Non-Apoptotic Cell Death Signaling Pathways in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2980.	4.1	39
7	BCL-w: apoptotic and non-apoptotic role in health and disease. <i>Cell Death and Disease</i> , 2020, 11, 260.	6.3	53
8	Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program. <i>Journal of Oncology</i> , 2019, 2019, 1-15.	1.3	26
9	Physiologically Relevant Oxygen Concentration (6% O ₂) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4203.	4.1	17
10	17-Aminogeldanamycin selectively diminishes IRE1 α -XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 596-611.	4.9	14
11	Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. <i>Molecular Carcinogenesis</i> , 2019, 58, 588-602.	2.7	37
12	Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. <i>Laboratory Investigation</i> , 2017, 97, 217-227.	3.7	28
13	Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. <i>PLoS ONE</i> , 2017, 12, e0183498.	2.5	10
14	Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. <i>Oncotarget</i> , 2016, 7, 9026-9040.	1.8	16
15	MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment. <i>PLoS ONE</i> , 2015, 10, e0128796.	2.5	10
16	Phenotypic diversity of patient-derived melanoma populations in stem cell medium. <i>Laboratory Investigation</i> , 2015, 95, 672-683.	3.7	22
17	Pro-Survival Role of MITF in Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 352-358.	0.7	72
18	MITF in melanoma: mechanisms behind its expression and activity. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 1249-1260.	5.4	229

#	ARTICLE	IF	CITATIONS
19	Natural Compounds' Activity against Cancer Stem-Like or Fast-Cycling Melanoma Cells. PLoS ONE, 2014, 9, e90783.	2.5	44
20	Gene Expression Profiling Identifies Microphthalmia-Associated Transcription Factor (MITF) and Dickkopf-1 (DKK1) as Regulators of Microenvironment-Driven Alterations in Melanoma Phenotype. PLoS ONE, 2014, 9, e95157.	2.5	26
21	Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Letters, 2013, 331, 24-34.	7.2	67
22	Parthenolide enhances dacarbazine activity against melanoma cells. Anti-Cancer Drugs, 2013, 24, 835-845.	1.4	23
23	Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 966-981.	1.7	24